跳至主要内容
临床试验/KCT0006755
KCT0006755招募中未知

Multicenter, Prospective Clinical Trial for Optimizing TNFi dose Adjustment in AS patients with Stable Disease Activity

Hanyang University0 个研究点目标入组 448 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
448

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 65(Year)(—)
性别
All

入选标准

  • Subjects enrolled in the study must meet all of the following inclusion criteria:
  • Aged between 18 and 65
  • Documented diagnosis of Ankylosing spondylitis (AS) and meet the modified New York classification criteria for AS
  • Subjects maintaining stable disease (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] < 4) with standard-dose subcutaneous tumor necrosis factor inhibitor (TNFi) treatment during previous 6 months from the screening
  • Ankylosing Spondylitis Disease Activity Score (ASDAS) < 2.1 at screening (Week -4) and baseline (Week 0)
  • In subjects treated with methotrexate or sulfasalazine, the dose should be maintained (methotrexate= 25mg/day, sulfasalazine = 3 g/day) during previous 4 weeks before screening
  • In subjects treated with systemic glucocorticoids, the dose should be less than 10mg/day of predinisolone or equivalent during at least 2 weeks from the screening
  • Subjects with stable dose of concomitant NSAID (including Cox2 inhibitors) during the 2 weeks from the randomization

排除标准

  • Subjects will be excluded from participating in the study if they meet any of the following criteria:
  • Exposure to more than 1 TNFi
  • History of hypersensitivity reaction to any TNFis
  • Subjects with concomitant fibromyalgia, as determined by the investigator
  • Subjects who have received any TNFis with reduced dosage
  • Presence of total spinal ankylosis (‘Bamboo spine’)
  • Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study
  • Subjects with a history of malignancies and lymphoproliferative disorder including lymphoma within 5 years (Basal cell carcinoma treated within previous 3 months and showing no evidence of recurrence, actinic keratosis, and treated cervical/colon carcinoma in situ were allowed.)
  • Subjects with current or history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac or neurological disease, as determined by the investigator
  • Subjects with significant laboratory abnormalities included but not limited to:
  • 1) AST/ALT > 3.0 X ULN
  • 2) White blood cell (WBC) < 3000/µL and/or absolute neutrophil count (ANC) < 1500/µL
  • 3) Platelet count <100,000/µL and/or hemoglobin level <8.5 g/dL
  • 4) Serum creatinine = 1.5 X ULN
  • Subjected with any high-potency opioids (ex. methadone, hydromorphone, morphine, oxycodone, oxymorphone, fentanyl, levorphanol, buprenorphine, meperidine)
  • Subjects with current acute or chronic viral hepatitis B or C or with human immunodeficiency virus (HIV) infection
  • Subjects planning to receive any live attenuated vaccinations after screening
  • Subjects has history of chronic alcohol abuse or drug abuse within 6 months from screening
  • Subjects concomitantly treated with systemic glucocorticoid (>10mg/day of prednisolone or equivalent doses)
  • Subjects with any other condition that, in the Investigator’s judgment, would make the subject unsuitable for inclusion in the study
  • 18) Patients who are contraindicated in administration of clinical investigational drugs
  • -Patients with hypersensitivity to drugs
  • -Patients at risk of sepsis or sepsis
  • - Infections, including chronic or localized infections, severe infections, opportunistic infections, including tuberculosis
  • patient with
  • - Congestive heart failure (New York Heart Association Grade III or IV status)

研究者

相似试验

Multicenter, Prospective Clinical Trial for... | 临床试验